Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

Cephalon

ChemGenex Pharmaceuticals

Information provided by (Responsible Party):

Teva Pharmaceutical Industries

ClinicalTrials.gov Identifier:

NCT00375219

First received: September 8, 2006

Last updated: February 21, 2013

Last verified: February 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	January 2014
Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	May 3, 2012